For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260325:nRSY1331Ya&default-theme=true
RNS Number : 1331Y India Capital Growth Fund Limited 25 March 2026
25 March 2026
India Capital Growth Fund Limited
LEI: 213800TPOS9AM7INH846
Results of Extraordinary General Meeting
India Capital Growth Fund Limited (the "Company"), the London listed
investment company focused on long-term investment opportunities in India's
mid-and small-cap sectors, announces the results of the Extraordinary General
Meeting held earlier today. Shareholders approved the implementation of a
five-year conditional performance related tender for up to 25% of the
Company's issued share capital and the introduction of an annual dividend, to
be paid semi-annually. Full details of these proposals were set out in the
circular to Shareholders published by the Company on 20 February 2026 (the
"Circular").
The resolution proposed in the Circular was duly passed on a poll as
follows:
For Against Abstain
% in favour
Special Resolution 1 11,507,074 321,274 31,779 97.28
ENDS
ENQUIRIES
Matt Lihou
Apex Fund and Corporate Services (Guernsey) Limited
+44 203 5303 600
indiacapitalbox@apexgroup.com (mailto:indiacapitalbox@apexgroup.com)
About India Capital Growth Fund
India Capital Growth Fund Limited, the London Stock Exchange's Main Market
listed investment company registered and incorporated in Guernsey, was
established to take advantage of long-term investment opportunities in
companies based in India. ICGF predominantly invests in listed mid and small
cap companies, although investments may also be made in large cap and private
Indian companies where the Investment Manager believes long-term capital
appreciation will be achieved. www.indiacapitalgrowth.com
(http://www.indiacapitalgrowth.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMFLFESVDIEFIR
Copyright 2019 Regulatory News Service, all rights reserved